| May 8 |
OKYO Pharma Announces Participation in May 2024 Investor Conferences
|
| Apr 30 |
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
|
| Apr 8 |
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
|
| Apr 2 |
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
|
| Mar 22 |
OKYO Pharma gains after positive results from Phase 2 dry eye disease trial
|
| Mar 22 |
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
|
| Mar 21 |
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
|
| Mar 20 |
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
|
| Feb 9 |
OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain
|
| Feb 9 |
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
|
